Overview of Current Type I/II Kinase Inhibitors

Zheng Zhao, Philip E. BournearXiv 2018 · DOI · arXiv

TL;DR

This paper provides a systematic structural review of the 42 kinase-targeting drugs approved by the FDA as of August 2018. By analyzing how these molecules bind to their targets, the authors categorize the vast majority as Type I or Type II inhibitors and highlight how specific "sub-pockets" in the protein are exploited to achieve the selectivity needed for cancer therapy.

What Problem Does This Paper Address?

Kinases are the "master switches" of the cell, responsible for phosphorylation—a process that regulates everything from growth to death. When these switches get stuck in the "on" position, the result is often cancer or autoimmune disease. While we know of over 500 human kinases, they all share a remarkably similar "pocket" where they bind ATP (their energy source).

The challenge for drug hunters is selectivity: how do you design a molecule that fits into one specific kinase's pocket without accidentally shutting down dozens of others? This paper addresses this by reviewing the structural "blueprints" of successful drugs to understand the mechanisms of action and the binding modes that lead to clinical success.

Methods

As a systematic review, the paper does not introduce a new laboratory technique or algorithm. Instead, it employs structural bioinformatics analysis. The authors analyzed co-crystal structures from the Protein Data Bank (PDB) to map exactly where drugs sit within the kinase domain. They specifically focused on the orientation of the DFG (Asp-Phe-Gly) motif, a highly conserved sequence that acts as a conformational switch, to classify inhibitors into four types (I through IV).

Datasets

The primary "dataset" for this study is the library of 42 FDA-approved kinase-targeted drugs (up to August 2018). For each drug, the authors identified representative PDB (Protein Data Bank) entries—3D molecular maps of the drug bound to its target protein. Key examples include:

  • PDB 4I22: Gefitinib bound to EGFR.
  • PDB 1OPJ: Imatinib (Gleevec) bound to ABL.
  • PDB 4W9X: Baricitinib bound to JAK.

Key Insights and Ideas

  • The Type I vs. Type II Divide: Most drugs (33/42) are Type I, meaning they bind the kinase in its "active" (DFG-in) state. Only 6 are Type II, which bind the "inactive" (DFG-out) state. Interestingly, the paper notes that Type II inhibitors are not inherently more selective than Type I, despite occupying an additional allosteric pocket.
  • Exploiting the "Sub-Pockets": To gain selectivity, Type I drugs don't just sit in the ATP hole; they "reach out" into adjacent regions like the front-pocket, the hydrophobic pocket, and the P-loop. For example, Gefitinib uses a morpholine group to interact with specific residues (C797 and D800) in the front pocket.
  • The Rise of Covalent Inhibitors: A significant trend is the use of "covalent" drugs (like Ibrutinib or Osimertinib). These molecules contain an "electrophilic warhead" (usually an acrylamide group) that forms a permanent chemical bond with a specific cysteine residue in the pocket, effectively "gluing" the inhibitor in place.
  • The "Popularity" Bias: A striking insight is that drug discovery is heavily concentrated. Most approved drugs target just a few kinases: VEGFR (8 drugs), EGFR (6), ABL (5), and ALK (4). This leaves over 100 disease-associated kinases largely unexplored.

Key Results

  • Classification Breakdown: Of the 42 approved drugs, 33 are Type I, 6 are Type II, and 3 are Type III (allosteric MEK inhibitors).
  • Mechanism of Resistance: The paper highlights how tumors fight back. For instance, the T790M mutation in EGFR creates "gatekeeper" resistance, while the C797S mutation prevents covalent drugs from binding, necessitating the development of 4th-generation inhibitors.
  • Combination Therapy: The authors point to the success of "drug cocktails," such as combining BRAF and MEK inhibitors, to bypass the complex signaling networks that cancer cells use to survive single-drug treatments.

Limitations and Future Work

  • The "Dark" Kinome: The authors acknowledge that current research is "stuck" on approximately 40 kinases. The major future challenge is expanding the druggable kinome to the other 100+ kinases associated with human disease.
  • Off-Target Toxicity: Despite structural insights, off-target binding remains a major cause of side effects and clinical trial failure. The paper suggests that future profiling must move beyond in vitro binding assays to more complex in vivo models.
  • Resistance Cycles: The "arms race" between drug design and tumor mutation (like the C797S mutation) means that structural biology must stay one step ahead of evolving cancer genomes.

Summary updated

Abstract

Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more kinase-related diseases. Currently, 42 kinase drugs have been approved by the FDA, most of which (39) are Type I/II inhibitors. Notwithstanding these advances, it is desirable to target additional kinases for drug development as more than 200 diseases, particularly cancers, are directly associated with aberrant kinase regulation and signaling. Here, we review the extant Type I/II drugs systematically to obtain insights into the binding pocket characteristics, the associated features of Type I/II drugs, and the mechanism of action to facilitate future kinase drug design and discovery. We conclude by summarizing the main successes and limitations of targeting kinase for the development of drugs.
BibTeX
@misc{zhao2018overview,
  author = {Zheng Zhao and Philip E. Bourne},
  title = {{Overview of Current Type I/II Kinase Inhibitors}},
  year = {2018},
  eprint = {1811.09718},
  archivePrefix = {arXiv},
  url = {https://arxiv.org/abs/1811.09718},
}
Figure